Compare ADMA Biologics Inc (ADMA) vs GameStop Corp. (GME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs GameStop Corp. — how do they compare? ADMA Biologics Inc trades at $9.95 (market cap $2.22B), while GameStop Corp. trades at $18.5 (market cap $8.44B). The key difference: GameStop Corp. is far larger — about 3.8× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.
| ADMA | GME | |
|---|---|---|
Market Cap | $2.22B | $8.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $27.69 |
52-Week Low | $7.60 | $18.79 |
Enterprise Value | $2.29B | $4.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
GME trades at $18.79, down 1.93% today, with a bearish technical signal from moving averages but oversold RSI readings. Recent earnings beats and a net income margin of 20.45% highlight improving profitability, though revenue declined to $3.82B in 2025. News indicates potential shifts in the proposed eBay acquisition strategy, moving toward a partnership instead of a full takeover.
The outlook is mixed: strong earnings momentum and low debt-to-asset ratio of 0.28 support upside, but bearish analyst consensus (16.67% buy) and revenue contraction pose risks. Investors face dilution concerns from a $1.4B debt-for-stock swap, while collectibles growth offers opportunity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →
